Personalized Immunotherapy: Adoptive Cell (TIL) Transfer

  My previous column from January 2016, “Personalized Immunotherapy: Therapeutic Cancer Vaccines” was Part 1 of a 2-Part series on “personalized” immunotherapies that are currently in clinical trials. As a recap, this is an entirely new model of drug therapy! Instead of standardized identical batches…

Read Full Post

Using the Innate Immune System to Fight Colorectal Cancer: CCR5 Antagonists

In previous The Currently Incurable Scientist columns I have focused on one arm of the immune system: the adaptive immune system. Immune system activating therapeutic vaccines and drugs such as PD-(L)1 inhibitors which remove immunosuppression interact with the adaptive immune system. But there is also…

Read Full Post

Research News – Personalized Cellular Immunotherapies 

We are excited to learn that Kite Pharma announced yesterday they will initiate personalized cellular immunotherapies before the end of 2016. These therapies will target certain sub-segments of the KRAS-mutant cancer patient population (KRAS-mutations are a biomarker of colorectal cancer). This new technology will use living immune cells as the…

Read Full Post

ASCO-2016: PRE CONFERENCE INSIGHTS

The American Society of Clinical Oncology (ASCO) annual meeting happens each June in Chicago. It is one of the premier meetings each year where oncologists, scientists and advocates gather to hear the latest clinical trial data in oncology, including focused sessions on GI cancers such…

Read Full Post

CRC Immunotherapy Blueprint Presented at AACR 2016

written by Dr. Tom Marsilje, Andrea (Andi) Dwyer, Nancy Roach and Anjee Davis Last December, Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI) brought together many of the world’s leading experts on CRC and immuno-oncology. (Read more about this meeting.) The meeting goal: To…

Read Full Post

Personalized Immunotherapy: Therapeutic Cancer Vaccines

I have already written a lot about experimental immunotherapies. Previous posts have ranged from the strong signs of clinical activity already seen by anti-PD1 checkpoint therapies in MSI-high Colorectal Cancer (CRC), to an overview of why the more common non-MSI CRC has been resistant to immunotherapy intervention, and finally a…

Read Full Post

A Blueprint to Advance Colorectal Cancer (CRC) Immunotherapies

On December 2, 2015 a remarkable meeting took place. Jointly organized by Fight Colorectal Cancer and the leading immuno-oncology organization the Cancer Research Institute, an unprecedented meeting gathered many of the world’s leading experts on both CRC and immuno-oncology. Top scientists devoted to CRC research…

Read Full Post

Reprogramming a Tumor for Death

In previous columns of The Currently Incurable Scientist, we’ve gone over a number of different types of colorectal cancer (CRC) experimental therapies – from targeted agents to various flavors of immunotherapies. In this installment, I want to introduce you to yet another area of intense…

Read Full Post

Releasing the PD-1 Brakes in MSI-high CRC Patients

Anti-PD-1 Pathway Immunotherapies – What’s All the Fuss? Immunotherapies have received an incredibly high amount of attention recently – with good cause! They are transforming treatment of multiple advanced major cancer types, e.g. melanoma and lung cancer, by using the immune system to fight the…

Read Full Post

Putting Out the Inflammation Fire

Scientists have recognized the problems caused by inflammation in cancer patients for years. In this month’s column I wanted to discuss a therapy in Phase 3 clinical trials for metastatic colorectal cancer (CRC) which is attempting to reduce chronic inflammation being caused by the disease….

Read Full Post
Page 1 of 212